Evidence map›Paper›PMID 33298191›Full record

ReviewClinical and translational allergy2020

Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study.

A Bédard, X Basagaña, J M Anto, J Garcia-Aymerich, P Devillier, S Arnavielhe, A Bedbrook, G L Onorato, W Czarlewski, R Murray and 71 more

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and translational allergy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK-air Study.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Guideline on allergen immunotherapy in IgE-mediated allergic diseases: S2K Guideline of the German Society of Allergology and Clinical Immunology (DGAKI), Society of Pediatric Allergology and Environmental Medicine (GPA), Medical Association of German Allergologists (AeDA), Austrian Society of Allergology and Immunology (ÖGAI), Swiss Society for Allergology and Immunology (SSAI), German Dermatological Society (DDG), German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), German Society of Pediatrics and Adolescent Medicine (DGKJ), Society of Pediatric Pulmonology (GPP), German Respiratory Society (DGP), German Professional Association of Otolaryngologists (BVHNO), German Association of Paediatric and Adolescent Care Specialists (BVKJ), Federal Association of Pneumologists, Sleep and Respiratory Physicians (BdP), Professional Association of German Dermatologists (BVDD).Allergologie select · 2022
    Article
  16. Review
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

81 authors.

A BédardISGlobal, Barcelona, Spain.
X BasagañaISGlobal, Barcelona, Spain.
J M AntoISGlobal, Barcelona, Spain.
J Garcia-AymerichISGlobal, Barcelona, Spain.
P DevillierUPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France.
S ArnavielheKYomed INNOV, Montpellier, France.
A BedbrookCHU de Montpellier, Montpellier, France.
G L OnoratoCHU de Montpellier, Montpellier, France.
W CzarlewskiMedical Consulting Czarlewski, Levallois, France.
R MurrayResearch fellow, OPC, and Director, Cambridge, UK.
R AlmeidaFaculdade de Medicina da Universidade do Porto, Lda Porto, Portugal.
J A FonsecaFaculdade de Medicina da Universidade do Porto, Lda Porto, Portugal.
J Correia da SousaLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.
E CostaFaculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (Porto4Ageing), Porto, Portugal.
M Morais-AlmeidaAllergy Center, CUF Descobertas Hospital, Lisbon, Portugal.
A Todo-BomImunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
L CecchiSOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.
G De FeoDepartment of Medicine, Surgery and Dentistry "Scuola Medica Salernitana, University of Salerno, Salerno, Italy.
M IllarioDivision for Health Innovation, Campania Region, Federico II University Hospital Naples (R&D and DISMET), Naples, Italy.
E MendittoCIRFF, Federico II University, Naples, Italy.
R MontiDepartment of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino, Mauriziano Hospital, Turin, Italy.
C StellatoUnit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy.
M T VenturaMedical School Saint Antoine, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM, Sorbonne Université, Paris, France.
I Annesi-MaesanoMedical School Saint Antoine, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM, Sorbonne Université, Paris, France.
I BosseAllergist La Rochelle, La Rochelle, France.
J F FontaineAllergist, Reims, France.
N Pham-ThiEcole Polytechnique Palaiseau, IRBA (Institut de Recherche bio-Médicale des Armées), Bretigny, France.
M ThibaudonRNSA (Réseau National de Surveillance Aérobiologique), Brussieu, France.
P Schmid-GrendelmeierAllergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
F SpertiniService Immunologie et Allergie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
N H ChavannesDepartment of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands.
W J FokkensDepartment of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, The Netherlands.
S ReitsmaDepartment of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, The Netherlands.
R DubakieneClinic of Chest Diseases, Immunology and Allergology, Medical Faculty, Vilnius University, Vilnius, Lithuania.
R EmuzyteClinic of Children's Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
V KvedarieneDepartment of Pathology, Faculty of Medicine and Clinic of Chest Diseases, Immunology and Allergology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Institute of Clinical Medicine, Vilnius, Lithuania.
A ValiulisVilnius University Institute of Clinical Medicine, Clinic of Children's Diseases, Department of Public Health, and Institute of Health Sciences, Vilnius, Lithuania.
P KunaDivision of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.
B SamolinskiDepartment of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.
L KlimekCenter for Rhinology and Allergology, Wiesbaden, Germany.
R MösgesMedical Faculty, CRI-Clinical Research International-Ltd, Institute of Medical Statistics, and Computational Biology, University of Cologne, Hamburg, Germany.
O PfaarDepartment of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
S ShamaiMedical Faculty, CRI-Clinical Research International-Ltd, Institute of Medical Statistics, and Computational Biology, University of Cologne, Hamburg, Germany.
R E Roller-WirnsbergerDepartment of Internal Medicine, Medical University of Graz, Graz, Austria.
P V TomazicDepartment of ENT, Medical University of Graz, Graz, Austria.
D RyanHonorary Clinical Research Fellow, Allergy and Respiratory Research Group, The University of Edinburgh, Edinburgh, UK.
A SheikhThe Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.
T HaahtelaSkin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.
S Toppila-SalmiSkin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.
E ValovirtaDepartment of Lung Diseases and Clinical Immunology, University of Turku, Terveystalo Allergy Clinic, Turku, Finland.
V CardonaAllergy Section, Department of Internal Medicine, Hospital Vall d'Hebron, ARADyAL Research Network, Barcelona, Spain.
J MullolRhinology Unit, & Smell Clinic, ENT Department, Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.
A ValeroPneumology and Allergy Department CIBERES and Clinical, & Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Barcelona, Spain.
M MakrisAllergy Unit "D Kalogeromitros", 2nd Dpt of Dermatology and Venereology, National & Kapodistrian University of Athens, "Attikon" University Hospital, Athens, Greece.
N G PapadopoulosDivision of Infection, & Respiratory Medicine, Royal Manchester Children's Hospital Immunity, University of Manchester, Manchester, UK.
E P ProkopakisDepartment of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece.
F PsarrosAllergy Department, Athens Naval Hospital, Athens, Greece.
C BachertUpper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium.
P W HellingsAcademic Medical Center, Univ of Amsterdam, Dept of Otorhinolaryngology, Univ Hospitals Leuven, Leuven, The Netherlands.
B PuginEuropean Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium.
C Bindslev-JensenOdense University Hospital, Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark.
E EllerOdense University Hospital, Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark.
I KullThermofisher Scientific, Uppsala, Sweden.
E MelénDepartment of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sach´s Children and Youth Hospital, Södersjukhuset, Sweden.
M WickmanSachs' Children and Youth Hospital, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
G De VriesCentre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden.
M van EerdCentre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden.
I AgachePeercode BV, Geldermalsen, The Netherlands.
I J AnsoteguiTransylvania University Brasov, Brasov, Romania.
S Bosnic-AnticevichDepartment of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain.
A A CruzNucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brazil.
T CasaleDivision of Allergy/Immunology, University of South Florida, Tampa, FLA, USA.
J C IvancevichClinica Santa Isabel, Servicio de Alergia e Immunologia, Buenos Aires, Argentina.
D E Larenas-LinnemannCenter of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico.
M SofievFinnish Meteorological Institute (FMI), Helsinki, Finland.
D WallaceNova Southeastern University, Fort Lauderdale, FL, USA.
S WasermanDepartment of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada.
A YorganciogluDepartment of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey.
D LauneKYomed INNOV, Montpellier, France.
J BousquetCHU de Montpellier, Montpellier, France. jean.bousquet@orange.fr.ORCID http://orcid.org/0000-0001-9226-7762
MASK study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe analysis of mobile health (mHealth) data has generated innovative insights into improving allergic rhinitis control, but additive information is needed. A cross-sectional real-world observational study was undertaken in 17 European countries during and outside the estimated pollen season. The aim was to collect novel information including the phenotypic characteristics of the users.

methodsThe Allergy Diary-MASK-air-mobile phone app, freely available via Google Play and App, was used to collect the data of daily visual analogue scales (VASs) for overall allergic symptoms and medication use. Fluticasone Furoate (FF), Mometasone Furoate (MF), Azelastine Fluticasone Proprionate combination (MPAzeFlu) and eight oral H1-antihistamines were studied. Phenotypic characteristics were recorded at entry. The ARIA severity score was derived from entry data. This was an a priori planned analysis.

results9037 users filled in 70,286 days of VAS in 2016, 2017 and 2018. The ARIA severity score was lower outside than during the pollen season. Severity was similar for all treatment groups during the pollen season, and lower in the MPAzeFlu group outside the pollen season. Days with MPAzeFlu had lower VAS levels and a higher frequency of monotherapy than the other treatments during the season. Outside the season, days with MPAzeFlu also had a higher frequency of monotherapy. The number of reported days was significantly higher with MPAzeFlu during and outside the season than with MF, FF or oral H1-antihistamines.

conclusionsThis study shows that the overall efficacy of treatments is similar during and outside the pollen season and indicates that medications are similarly effective during the year.

Indexed as

Allergic rhinitisAnti-histaminesCorticosteroidsICTMASKMobile healthTreatment

Identifiers

PMID33298191
PMCPMC7726888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.